Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 15/20 | 0.46 |
| ▸ | THRB | P10828 | 15/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515768 | 0.94 | HTT (0.49) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6522316 | 0.94 | SMN1; SMN2 (0.49) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6511313 | 0.93 | THRA (0.48) | THRATHRBHTTSMN1; SMN2MAPT | |
| SCHEMBL6513401 | 0.92 | THRB (0.48) | THRATHRBMAPT | |
| SCHEMBL6510883 | 0.90 | SMN1; SMN2 (0.48) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6514238 | 0.90 | SMN1; SMN2 (0.48) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6514008 | 0.88 | SMN1; SMN2 (0.49) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6520233 | 0.88 | THRB (0.56) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6512865 | 0.88 | THRB (0.56) | THRATHRBHTTSMN1; SMN2LMNA | |
| SCHEMBL6513939 | 0.86 | MAPT (0.51) | THRATHRBHTTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRA 2460/4885THRB 1772/4885HTT 399/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRA 1917/4885THRB 1835/4885HTT 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.